UK markets close in 3 hours 4 minutes

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
33.38-12.22 (-26.80%)
As of 7:02PM GMT. Market open.
Full screen
Previous close45.60
Open44.90
Bid0.00 x N/A
Ask0.00 x N/A
Day's range44.25 - 44.90
52-week range44.25 - 44.90
Volume9
Avg. volumeN/A
Market cap1.635B
Beta (5Y monthly)2.12
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
    Zacks

    Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

    Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

  • Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
    Motley Fool

    Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript

    As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of our most recent quarterly report on Form 10-Q, which is on file with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.

  • Here's Why Editas Medicine Dropped Today
    Motley Fool

    Here's Why Editas Medicine Dropped Today

    Shares of Editas Medicine (NASDAQ: EDIT) are down 10.7% at 1:50 p.m. EST today on no apparent news other than it's a high-flying biotech that's fallen out of favor with biotech investors of late. Investors are likely still a little spooked about a change in leadership at Editas after James Mullen took over the CEO role from Cynthia Collins earlier this month.